
Biodesix (BDSX) Stock Forecast & Price Target
Biodesix (BDSX) Analyst Ratings
Bulls say
Biodesix is a commercial-stage diagnostics company focused primarily on lung diseases and their diagnosis. With a focused, multi-omic pure-play in this space, including proprietary AI technology and a suite of blood-based tests that address immediate clinical needs, the company has demonstrated strong revenue growth and increasing gross margins. Additionally, the company's Development Services segment serves not just as a revenue generator, but also as a source of valuable biological insights for the company's pipeline. However, potential factors that could impact Biodesix's future growth include payor concentration risks, ongoing market education efforts for its tests, and the volatility and uncertainty surrounding reimbursement rates and commercial payor coverage decisions.
Bears say
Biodesix is heavily dependent on Medicare reimbursement, has limited access to capital as a small public company, and faces significant competition in other areas of diagnostic testing. Additionally, the company has reported negative operating cash flows and may have difficulty achieving and sustaining profitability. These factors contribute to my negative outlook on Biodesix's stock.
This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.
Biodesix (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares